Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Minji Sohn 3 Articles
Drug/Regimen
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim
Diabetes Metab J. 2024;48(2):253-264.   Published online January 26, 2024
DOI: https://doi.org/10.4093/dmj.2023.0128
  • 2,248 View
  • 353 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We investigated the long-term efficacy and safety of initial triple therapy using metformin, a dipeptidyl peptidase-4 inhibitor, and a sodium-glucose cotransporter-2 inhibitor, in patients with type 2 diabetes mellitus.
Methods
We enrolled 170 drug-naïve patients with glycosylated hemoglobin (HbA1c) level >7.5% who had started triple therapy (metformin, sitagliptin, and empagliflozin). Glycemic, metabolic, and urinary parameters were measured for 24 months.
Results
After 24 months, HbA1c level decreased significantly from 11.0%±1.8% to 7.0%±1.7%. At 12 and 24 months, the rates of achievement of the glycemic target goal (HbA1c <7.0%) were 72.5% and 61.7%, respectively, and homeostasis model assessment of β-cell function and insulin resistance indices improved. Whole-body fat percentage decreased by 1.08%, and whole-body muscle percentage increased by 0.97% after 24 months. Fatty liver indices and albuminuria improved significantly. The concentration of ketone bodies was elevated at the baseline but decreased after 24 months. There were no serious adverse events, including ketoacidosis.
Conclusion
Initial triple combination therapy with metformin, sitagliptin, and empagliflozin led to achievement of the glycemic target goal, which was maintained for 24 months without severe hypoglycemia but with improved metabolic function and albuminuria. This combination therapy may be a good strategy for drug-naïve patients with type 2 diabetes mellitus.
Others
Glucose Regulation after Partial Pancreatectomy: A Comparison of Pancreaticoduodenectomy and Distal Pancreatectomy in the Short and Long Term
Jun Suh Lee, Minji Sohn, Kyuho Kim, Yoo-Seok Yoon, Soo Lim
Diabetes Metab J. 2023;47(5):703-714.   Published online June 22, 2023
DOI: https://doi.org/10.4093/dmj.2022.0205
  • 1,786 View
  • 158 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Long term quality of life is becoming increasingly crucial as survival following partial pancreatectomy rises. The purpose of this study was to investigate the difference in glucose dysregulation after pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
Methods
In this prospective observational study from 2015 to 2018, 224 patients who underwent partial pancreatectomy were selected: 152 (67.9%) received PD and 72 (32.1%) received DP. Comprehensive assessment for glucose regulation, including a 75 g oral glucose tolerance test was conducted preoperatively, and 1, 12, and 52 weeks after surgery. Patients were further monitored up to 3 years to investigate development of new-onset diabetes mellitus (NODM) in patients without diabetes mellitus (DM) at baseline or worsening of glucose regulation (≥1% increase in glycosylated hemoglobin [HbA1c]) in those with preexisting DM.
Results
The disposition index, an integrated measure of β-cell function, decreased 1 week after surgery in both groups, but it increased more than baseline level in the PD group while its decreased level was maintained in the DP group, resulting in a between-group difference at the 1-year examination (P<0.001). During follow-up, the DP group showed higher incidence of NODM and worsening of glucose regulation than the PD group with hazard ratio (HR) 4.29 (95% confidence interval [CI], 1.49 to 12.3) and HR 2.15 (95% CI, 1.09 to 4.24), respectively, in the multivariate analysis including dynamic glycemic excursion profile. In the DP procedure, distal DP and spleen preservation were associated with better glucose regulation. DP had a stronger association with glucose dysregulation than PD.
Conclusion
Proactive surveillance of glucose dysregulation is advised, particularly for patients who receive DP.
Drug/Regimen
Effect of Lactobacillus plantarum LMT1-48 on Body Fat in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
Minji Sohn, Hyeyoung Jung, Woo Shun Lee, Tai Hoon Kim, Soo Lim
Diabetes Metab J. 2023;47(1):92-103.   Published online April 29, 2022
DOI: https://doi.org/10.4093/dmj.2021.0370
  • 9,134 View
  • 390 Download
  • 11 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We investigated whether Lactobacillus plantarum strain LMT1-48, isolated from Korean fermented foods and newborn feces, is a suitable probiotic supplement to treat overweight subjects.
Methods
In this randomized, double-blind, placebo-controlled clinical trial, 100 volunteers with a body mass index of 25 to 30 kg/m2 were assigned randomly (1:1) to receive 2×1010 colony forming units of LMT1-48 or to a placebo treatment group. Body composition was measured by dual-energy X-ray absorptiometry, and abdominal visceral fat area (VFA) and subcutaneous fat area were measured by computed tomography scanning. Changes in body fat, VFA, anthropometric parameters, and biomarkers were compared between the two treatment groups (ClinicalTrials.gov number: NCT03759743).
Results
After 12 weeks of treatment, the body weight decreased significantly from 76.6±9.4 to 75.7±9.2 kg in the LMT1-48 group but did not change in the placebo group (P=0.022 between groups). A similar pattern was found in abdominal VFA between the two groups (P=0.041). Serum insulin levels, the corresponding homeostasis model assessment of insulin resistance, and leptin levels decreased in the LMT1-48 group but increased in the placebo group (all P<0.05). Decrease in body weight and body mass index by treatment with LMT1-48 was correlated with increase in Lactobacillus levels significantly. LMT1-48 also increased Oscillibacter levels significantly, which were negatively correlated with triglyceride and alanine transaminase levels.
Conclusion
Administration of LMT1-48 decreased body weight, abdominal VFA, insulin resistance, and leptin levels in these subjects with overweight, suggesting its anti-obesogenic therapeutic potential.

Citations

Citations to this article as recorded by  
  • Beneficial effects of the probiotics and synbiotics supplementation on anthropometric indices and body composition in adults: A systematic review and meta‐analysis
    Saeede Saadati, Kaveh Naseri, Omid Asbaghi, Mohsen Yousefi, Elnaz Golalipour, Barbora de Courten
    Obesity Reviews.2024;[Epub]     CrossRef
  • The Effect of Lactobacillus plantarum on the Fecal Microbiota, Short Chain Fatty Acids, Odorous Substances, and Blood Biochemical Indices of Cats
    Bing Han, Shukun Liang, Jintao Sun, Hui Tao, Zhenlong Wang, Baosheng Liu, Xiumin Wang, Jie Liu, Jinquan Wang
    Microorganisms.2024; 12(1): 91.     CrossRef
  • Natto alleviates hyperlipidemia in high-fat diet-fed mice by modulating the composition and metabolic function of gut microbiota
    Le-Yuan Shang, Shuo Zhang, Min Zhang, Xiao-Dong Sun, Qi Wang, Yu-Jie Liu, Yan-Ni Zhao, Mei Zhao, Peng-Jiao Wang, Xiu-Li Gao
    Journal of Functional Foods.2024; 112: 105968.     CrossRef
  • Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity
    Oladayo Emmanuel Apalowo, Grace Adeola Adegoye, Tolulope Mobolaji Obuotor
    Current Issues in Molecular Biology.2024; 46(3): 1810.     CrossRef
  • Anti-obesogenic effects of plant natural products: A focus on Korean traditional foods
    Gitishree Das, Luis Alfonso Jiménez Ortega, Sandra Gonçalves, J. Basilio Heredia, Maria de Lourdes Gomes Pereira, Anabela Romano, Han-Seung Shin, Jayanta Kumar Patra
    Trends in Food Science & Technology.2024; : 104470.     CrossRef
  • A 12-Week, Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial for the Evaluation of the Efficacy and Safety of Lactiplantibacillus plantarum SKO-001 in Reducing Body Fat
    Seon Mi Shin, Jeong-Su Park, Sang Back Kim, Young Hee Cho, Hee Seo, Hak Sung Lee
    Nutrients.2024; 16(8): 1137.     CrossRef
  • Efficacy and Safety of WCFA19 (Weissella confusa WIKIM51) in Reducing Body Fat in Overweight and Obese Adults
    Hwayeon Sun, Jinyoung Shin, Min-ji Kim, Sunghwan Bae, Nicole Dain Lee, Byungwook Yoo
    Journal of Clinical Medicine.2024; 13(9): 2559.     CrossRef
  • 3D printing of microencapsulated Lactobacillus rhamnosus for oral delivery
    Pablo Rosas-Val, Masoud Adhami, Ana Brotons-Canto, Carlos Gamazo, Juan M. Irache, Eneko Larrañeta
    International Journal of Pharmaceutics.2023; 641: 123058.     CrossRef
  • Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
    Kyoung Jin Choi, Mi Young Yoon, Ji-Eun Kim, Sang Sun Yoon
    Scientific Reports.2023;[Epub]     CrossRef
  • Ameliorating Effects of Bifidobacterium longum subsp. infantis FB3-14 against High-Fat-Diet-Induced Obesity and Gut Microbiota Disorder
    Ruixin Kou, Jin Wang, Ang Li, Yuanyifei Wang, Bowei Zhang, Jingmin Liu, Yi Sun, Shuo Wang
    Nutrients.2023; 15(19): 4104.     CrossRef
  • Effect of Continuous Ingestion of Bifidobacteria and Inulin on Reducing Body Fat: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study
    Yuhei Baba, Yasuo Saito, Mei Kadowaki, Naoki Azuma, Daisuke Tsuge
    Nutrients.2023; 15(24): 5025.     CrossRef
  • A Review of the Potential of Probiotic Bacteria in Managing the Body Weight of Obese Individuals
    A Didban, L Manafi, R Mahmoudi
    Journal of Health and Hygiene.2023; 14(4): 388.     CrossRef
  • Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves the Gut Microbiota Associated with Hepatic Disorders: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial
    Narandalai Danshiitsoodol, Masafumi Noda, Keishi Kanno, Tomoyuki Uchida, Masanori Sugiyama
    Nutrients.2022; 14(21): 4492.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal